Ganaplacide API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Ganaplacide API 1261113-96-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Ganaplacide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ganaplacide
- Synonyms:
- 2-Amino-1-[2-(4-fluorophenyl)-3-[(4-fluorophenyl)amino]-5,6-dihydro-8,8-dimethylimidazo[1,2-a]pyrazin-7(8H)-yl]ethanone , Ganaplacide
- Cas Number:
- 1261113-96-5
- DrugBank number:
- DB16173
- Unique Ingredient Identifier:
- 85VMN9JU7A
General Description:
Ganaplacide, identified by CAS number 1261113-96-5, is a notable compound with significant therapeutic applications. Ganaplacide is under investigation in clinical trial NCT03167242 (Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria).
Ganaplacide is a type of Antimalarial
The Antimalarial category of pharmaceutical APIs encompasses a range of active ingredients used in the development of drugs to treat and prevent malaria, a life-threatening infectious disease caused by the Plasmodium parasite. These APIs are crucial in formulating effective antimalarial medications.
One widely used API in this category is Artemisinin, derived from the Artemisia annua plant. It exhibits potent antimalarial properties and is a key component in various combination therapies. Another prominent API is Chloroquine, an aminoquinoline compound that has been historically used as a primary treatment for malaria. However, due to emerging drug resistance, alternative APIs like Mefloquine and Quinine have gained prominence.
These APIs work by interfering with the life cycle of the Plasmodium parasite. They inhibit various stages of parasite development, such as preventing the replication of the parasite's DNA and disrupting its metabolic processes. By targeting the parasite, antimalarial APIs help to control and eliminate the infection, reducing the severity of symptoms and preventing complications.
The development and production of high-quality antimalarial APIs require stringent quality control measures to ensure their safety and efficacy. Pharmaceutical companies adhere to strict regulations and guidelines to guarantee the purity, stability, and bioavailability of these APIs. Additionally, ongoing research aims to discover new antimalarial APIs and formulations to combat drug resistance and improve treatment outcomes.
In conclusion, the Antimalarial category of pharmaceutical APIs plays a vital role in the formulation of drugs used to treat and prevent malaria. These APIs, such as Artemisinin, Chloroquine, Mefloquine, and Quinine, effectively target the Plasmodium parasite, aiding in the management and eradication of malaria infections.
